



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Review

Membrane transport proteins in melanosomes: Regulation of ions for pigmentation



Pattama Wiriyasermkul¹, Satomi Moriyama¹, Shushi Nagamori*

Department of Collaborative Research for Bio-Molecular Dynamics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan

ARTICLE INFO

Keywords:

Transporter
Ion transport
Neutral pH
Tyrosinase
Melanocyte
Melanin

ABSTRACT

Melanosomes are unique organelles in melanocytes that produce melanin, the pigment for skin, hair, and eye color. Tyrosinase is the essential and rate-limiting enzyme for melanin production, that strictly requires neutral pH for activity. pH maintenance is a result of the combinational function of multiple ion transport proteins. Thus, ion homeostasis in melanosomes is crucial for melanin synthesis. Defect of the ion transport system causes various pigmentation phenotypes, from mild effect to severe disorders such as albinism. In this review, we summarize the up-to-date knowledge of the ion transport system, such as transport function, structure, and the physiological roles and mechanisms of the ion transport proteins in melanosomes. In addition, we propose a model of melanosomal ion transport system—how the functional coupling of multiple transport proteins modulates and maintains ion homeostasis. We discuss melanin synthesis in terms of the ion transport system.

1. Introduction

Melanosome (~500 nm in diameter) is a large unique organelle found in skin and hair melanocytes, and retinal pigment epithelial cells [1]. Melanosomes are responsible for synthesis, storage, and transport of melanin. The main roles of melanin are pigmentation (skin, hair and eye color) and defense mechanism against ultraviolet radiation and mechano-stress [1–5]. Unlike retinal epithelial cells where melanosomes are matured and the pigment is settled during development, melanocytes in skin and hair continuously produce melanosomes throughout life [1]. Originating from endosomes, melanosome is a member of lysosome-related organelles (LROs) and shares some characteristics and pathways with those of lysosome; similarities include biogenesis, maturation, trafficking (exo/endocytosis), recycling and migration [6,7]. However, melanosome biogenesis exhibits unique processes and specifically takes place in melanocytes. Newly mature melanosomes migrate from melanocytes to keratinocytes, resulting in pigmentation of epithelial cells (Fig. 1) [1,6,8]. As there are multiple processes, several protein molecules are involved in melanosome biogenesis, trafficking, and migration. Alterations of each corresponding molecule undoubtedly contribute to the variation of skin and eye color as well as ocular and dermatological diseases such as retinal pigment epitheliopathy, albinism, hyperpigmentation disorders, and skin

cancers [4,9,10].

Membrane transport proteins (i.e., transporters, channels and pumps) in melanosomes have shown strong correlations to melanosome biogenesis. Some of these membrane transport proteins including OCA2 (oculocutaneous II), SLC45A2 (solute carrier 45 member 2), SLC24A5 (solute carrier 24 member 5), TPC2 (two-pore channel protein 2) and ATP7A (copper-transporting ATPase 1) have been predicted to modulate melanosomal pH and contribute to the activity of tyrosinase (TYR), an essential protein for melanin production [11]. Previous studies indicated that mutations and polymorphisms of these transport proteins are strongly associated with oculocutaneous albinism (OCA) [4]. Until present, several causative mutations have been identified. However, the roles or transport functions of the transport proteins in melanogenesis are still poorly understood. In this review, we highlight the current progress of the research of membrane transport proteins in melanosomes and melanogenesis. Specifically, transport function, roles in melanogenesis, and significant causative mutation are summarized here. Furthermore, we predict 3D structures of the transport proteins and discuss the unknown functions of these membrane transport proteins in melanosomes.

Abbreviations: TYR, tyrosinase; TYRP1, tyrosinase-related protein 1; TYRP2, tyrosinase-related protein 2; OCA, oculocutaneous albinism; OCA2, oculocutaneous albinism 2; SLC45A2, solute carrier 45 member 2; SLC24A5, solute carrier 24 member 5; TPC2, two-pore channel 2; ATP7A, copper-transporting ATPase 1

* Corresponding author.

E-mail address: snagamori@nagamori-lab.jp (S. Nagamori).

¹ These authors contributed equally to this work.

<https://doi.org/10.1016/j.bbamem.2020.183318>

Received 31 March 2020; Received in revised form 17 April 2020; Accepted 18 April 2020

Available online 22 April 2020

0005-2736/ © 2020 Elsevier B.V. All rights reserved.




Fig. 1. Schematic of epidermis layers and melanosome biogenesis in melanocytes. Melanocytes and keratinocytes are cells located in epidermis layers (left). Melanogenesis takes place in melanosome, a unique organelle in melanocytes. Melanosome is developed from the early endosome. Melanosome formation and maturation are called biogenesis, which is composed of four stages. Stages I–II are the nonpigmented stages of melanosomes, called premelanosomes. In premelanosomes, PMEL fibrils are formed (stage I), and completely organized as parallel sheets in ellipsoidal shape (stage II). Melanogenesis pathway begins at stage III, the stage which TYR along with TYRPs, ATP7A, OCA2, SLC45A2, and TPC2 are translocated from trans-Golgi network to melanosomes. The premelanosomes have acidic pH, but stages III–IV melanosomes have neutral pH, which may be a result of combinational function of the newly deposited ion transport proteins. Under neutral pH, TYR is functional and melanin is synthesized. Synthesized melanins fully mask on PMEL fibrils at stage IV, resulting in mature melanosome. Mature melanosomes are delivered to keratinocytes and are distributed throughout the skin.

2. Melanin and melanogenesis

Melanin is a group of pigments made up of heterogeneous polymers and is widely found in animals, plants, protozoa, eubacteria, and some fungi [5]. Melanin has a broad absorption spectrum and a high optical refractive index, enabling intriguing biological properties; such as UV light absorption and scattering, free radical scavenging, ion storage, metal chelation, and electromagnetic field sensing [2,5,12]. Animals have two major types of melanin: brown-black eumelanin and red-yellow pheomelanin. While eumelanin in the skin is the major factor contributing to skin color (dark or light skins), the ratio of eumelanin and pheomelanin in the hair determines diverse shades of hair color. Because both types of melanin have distinct chemical structures and optical properties, the response to UV radiation and reactive oxygen species (ROS) are different. Pheomelanin is less protective against UV radiation and ROS than eumelanin, leading to UV-radiation-dependent melanoma risk [2,13]. In addition, the intrinsic pheomelanin synthesis pathway produces UV-radiation-independent contributors to melanogenesis [14]. Consequently, people who have red hair/fair skin (phenotypes of low eumelanin) are at greater risk for skin cancer.

Melanogenesis is a melanin synthesis pathway occurring in melanosomes (Fig. 2). The first step in melanogenesis is hydrolyzation of L-tyrosine to L-DOPA by tyrosinase (TYR). TYR also oxidizes L-DOPA into dopaquinone. Depending on the availability of L-cysteine and the function of downstream enzymes, different types of melanin are produced. The eumelanin synthesis pathway is quite well studied compared to the pheomelanin synthesis pathway. The production of eumelanin occurs in the absence of L-cysteine. Dopaquinone is converted into two intermediates: 5,6-dihydroxylindole-2-carboxylic acid (DHICA) and 5,6-dihydroxyl indole (DHI), then finally converted to eumelanin. These processes require enzymatic reactions of TYR and two other enzymes, dopachrome tautomerase (DCT/TYRP2/TRP2) and tyrosinase-related protein 1 (TYRP1/TRP1). In the presence of L-cysteine, dopaquinone is converted into cysteinylDOPA instead. The cysteinylDOPA passes several enzymatic reactions involving oxidation and polymerization yielding pheomelanin (Fig. 2) [4,15,16].




Fig. 2. Pathway of melanogenesis. In melanin production, tyrosinase (TYR) is a rate-limiting enzyme that converts L-tyrosine to L-DOPA, and subsequently, to dopaquinone. In the absence of L-cysteine, dopaquinone is finally converted to eumelanin. TYRP1 and TYRP2 (DCT) are tyrosinase-related proteins that contribute to the processes of eumelanin synthesis. Pheomelanin is synthesized under the presence of L-cysteine via several precursors.

TYR and TYRPs belong to tyrosinase family [16]. Production of melanin (eumelanin) is dependent on the activities of TYR and TYRPs in which TYR is the rate-limiting enzyme [17]. TYR is known to be controlled by either mRNA expression or protein function. TYR mRNA expression is regulated via the melanocortin 1 receptor (MC1R)-dependent cyclic adenosine monophosphate (cAMP) signaling pathway. MC1R is a G-protein coupled receptor (GPCR) on melanocytes that

senses melanocyte stimulating hormone (MSH) and mediates cAMP signaling to regulate the microphthalmia-associated transcription factor (MITF). MITF thereby regulates the TYR mRNA expression as well as other aspects of melanosomes/melanocytes [3,18]. Functional control of TYR protein is accomplished by modulation of melanosomal pH because TYR activity is solely dependent on pH. Neutral pH preserves TYR and TYRPs functions, while acidic pH suppresses TYR function without altering its expression (discussed in later section). Zhou et al. reported that the soluble adenylyl cyclase (sAC)-dependent pathway negatively modulates melanin production by decreasing the pH of melanosomes [19].

3. Melanosome biogenesis

Both melanosomes and lysosomes originate from multivesicular endosomes. However, melanosome formation occurs through distinct pathways in melanocytes in which several unique proteins are involved [7,11,20]. Melanosome biogenesis (referred to eumelanosome biogenesis), the process of melanosome development and maturation, is composed of four different stages (Fig. 1). Melanosomes at stages I–II, also called premelanosomes, lack melanin production but contain the formation of amyloid fibrils composed of the melanocyte protein PMEL (also known as PMEL17 and gp100). The characteristic of melanosomes at stage I is similar to the early endosome, which contains intraluminal vesicles (ILVs). In this stage, PMEL is cleaved into M α and M β fragments. The M α fragments dissociate from the luminal domain and start to nucleate at the ILVs to form tiny non-rearranged fibrils. During stage II, the formation of the fibrils, called PMEL fibrils, is completed. PMEL fibrils are organized and elongated as arrays of parallel sheets in an ellipsoidal shape of melanosome, serving as a matrix for melanin deposition which is initiated at stage III and completed at stage IV (Fig. 1) [7,21]. At stage III, several enzymes (TYR, TYRP1 and TYRP2) and ion transport proteins (ATP7A, OCA2, SLC45A2 and TPC2) for melanogenesis are sorted from trans-Golgi network to melanosome, and then, melanogenesis begins [11,20,22,23]. Synthesized melanin moves on and covers the PMEL fibrils completely at stage III and thickens and darkens as shown at stage IV. In skin, the mature melanosomes enter the process of migration from melanocytes to keratinocytes resulting in the spread of skin colors [1,5,6,8]. In hair follicles, stages of melanosome biogenesis, melanogenesis and melanosome transfer are similar to those of melanocytes in epidermis. Melanosome biogenesis occurs in follicular melanocytes located in hair bulbs during the anagen stage of hair cycle. Due to the distinct anatomic compartments, follicular melanocytes have more dendritic, extensive Golgi apparatus and rough endoplasmic reticulum, and produce larger mature melanosomes than epidermal melanocytes [24].

4. Ions and ion transport proteins

Ion transport proteins, including ion channels, pumps and transporters, play significant roles in multiple cellular activities at plasma membranes and intracellular organelles. The function of a transport protein relies on the electrochemical gradients. Channels selectively facilitate passive diffusion. Active transport systems move the substances against their electrochemical gradients. Primary active transport proteins hydrolyze ATP to mediate active transport. Secondary active transport proteins utilize energy from the electrochemical gradients, such as Na⁺, to drive the active transport. Tertiary active transport proteins mediate exchange or cotransport by using the energy derived from the chemical gradients generated by the secondary active transport proteins [25]. The maintenance of ion homeostasis requires the combinational function of ion transport proteins. In melanosomes, ions are indispensable factors that define the nature of the organelle for melanogenesis as well as its biogenesis. The ions and their transport proteins contribute to enzymatic reactions, redox reaction, electrical signaling, metal and ionic homeostasis, and pH maintenance. In the

following section, the roles of both ions and ion transport proteins for melanosomes are discussed.

5. Ions and ion transport in melanogenesis

Ions are important for melanogenesis and melanosomal maintenance in either direct or indirect aspects. pH and Cu²⁺ are obligatory factors for TYR function. Ca²⁺ is suggested to be essential for Ca²⁺-mediated signaling pathways and homeostasis between melanosomes and melanocytes. Here, we describe the roles of pH, Cu²⁺ and Ca²⁺ in melanosomes. The importance of other ions, Na⁺, K⁺, and Cl⁻ in melanogenesis, has not been directly revealed. However, two aspects are proposed below. The first aspect is based on the physiological function of Na⁺ and K⁺ for maintenance of membrane potential. The K⁺ concentration gradient determines membrane potential and Na⁺ is required during polarization/depolarization. Therefore, Na⁺ and K⁺ may contribute to the maintenance of membrane potential in melanosomes. Cl⁻ and Ca²⁺ may also be involved in maintaining the membrane potential. The second aspect is that Na⁺, Ca²⁺, and Cl⁻ are coupled substrates of ion transport proteins which are important for modulation of melanosomal pH during stages III–IV. The pH maintenance requires the functional combination of multiple ion transport proteins such as OCA2, SLC45A2, and TPC2. OCA2 mediates Cl⁻ conductance and TPC2 shows the properties of Na⁺ and/or Ca²⁺ efflux (see in later section). Thus, it is highly possible that Na⁺, Ca²⁺ and Cl⁻ participate in the pH maintenance of melanosomes.

5.1. pH and H⁺

pH plays a critical role in melanogenesis. Melanosomes in different stages have different internal pH. Premelanosomes exhibit acidic pH while stages III–IV melanosomes show neutral pH. PMEL fibrils are rapidly formed under strict acidic condition of premelanosomes [26,27]. However, TYR and TYRPs, which are expressed in stages III–IV melanosomes, are active at neutral pH and have diminished activity in acidic conditions [28–31]. Neutral pH promotes eumelanin synthesis by maintaining the full activity of TYR as observed in melanosomes of the melanocytes from Black skin. In contrast, melanosomes of melanocytes from Caucasians are more acidic, and their TYR is largely inactive. Rescue experiments using NH₄Cl to increase melanosomal pH confirmed the importance of pH in TYR activity. Caucasian melanocytes treated with NH₄Cl show an increase of TYR activity whereas Black melanocytes do not change the TYR activity with NH₄Cl treatment [30]. Acidification also suppresses the eumelanin synthesis at the later steps after dopachrome (Fig. 2) [31]. Moreover, weak acidic pH promotes the pheomelanin production pathway [32]. These results demonstrate that during melanosome maturation at stages II–III the melanosomal pH changes from acidic to neutral thereby terminating PMEL polymerization steps and, instead, initiating TYR function.

Vacuolar H⁺-ATPase (V-ATPase) is a H⁺ pump expressed in all stages of melanosomes. V-ATPase mediates H⁺ influx resulting in acidic pH in premelanosomes [33]. In stages III–IV melanosomes, there must be some types of machinery to modulate acidic pH into neutral pH—either suppressing V-ATPase activity or clearing out the H⁺. Failure to neutralize the pH results in acidic melanosomes and lowered melanin production. The role of V-ATPase as a negative pH regulator in melanin production is confirmed by Caucasian melanocytes and animal cell models. Inhibition of V-ATPase in acidic melanosomes by bafilomycin or concanamycin rescues the failure of the melanin production but the treatment has no effect in melanosomes which have neutral pH [28–30,34,35].

In physiological condition, stages III–IV melanosomes would express a transport protein(s) that fluxes H⁺ out. SLC45A2 (MATP/AIM1) is the most promising molecule. SLC45A2 belongs to the H⁺/sugar cotransporter family [36]. Knockdown of SLC45A2 results in melanosomal acidification, which interrupts TYR activity in the cell models




Fig. 3. Ion transport proteins in melanosomes.

V-ATPase, a H^+ pump, is expressed since stage I premelanosomes, generating acidic pH in premelanosomes. TYR along with other ion transport proteins are expressed in stages III–IV melanosomes. ATP7A is a Cu^{2+} pump, supplying Cu^{2+} as a cofactor for TYR. OCA2 and SLC45A2 are positive regulators for TYR function (black dash arrows) while TPC2 is negative regulator (black dash line with blunt end).

Transport properties and substrates of OCA2, SLC45A2 and TPC2 are proposed. Combinational function of these proteins is suggested to switches acidic pH into neutral pH (orange dash lines), which corresponds to the termination of stage II and initiation of stage III melanosomes. pH neutralization serves as the optimal environmental platform for TYR function, leading to melanin production during stages III–IV melanosomes (orange arrow).

[37]. In albino zebrafish with a *SLC45A2* mutation, the TYR activity is disrupted, but rescued by reinjection of *SLC45A2* mRNA or bafilomycin treatment [35]. Although *SLC45A2* transport activity in melanosomes is unclear, it is proposed that *SLC45A2* effluxes H^+ coupled with substrates and neutralizes the pH of stages III–IV melanosomes (Fig. 3). Additionally, voltage-gated Cl^-/H^+ exchangers (ClCs) and Na^+/H^+ exchangers (NHEs) may be candidates participating in H^+ export. ClC-7 mediates H^+ efflux in lysosome to control lysosomal pH. Mutation in *ClC-7* gene causes hyperacidification and results in albinism [38]. Thus, it is possible that ClC-7 is also expressed in melanosomes. NHE3 and NHE7 are colocalized with TYRP1 in melanocytes, although the function of NHEs in melanosomes has not yet been demonstrated [39].

To date, the mechanism of pH regulation in melanosomes has not been revealed. However, several studies clearly indicate that multiple ion transport proteins participate in the regulation of melanosomal pH (Fig. 3). OCA type 2 (OCA2/P) and SLC45A2 (MATP/AIM1) proteins are reported to be positive regulators for pH neutralization [35,40]. Two-pore channel 2 (TPC2) was found to be a negative regulator for pH neutralization [41]. OCA2 and TPC2 are ion transport proteins but may not directly transport H^+ . The proposed roles and functions of these proteins are discussed in later section.

5.2. Cu^{2+} and Zn^{2+}

Cu^{2+} and Zn^{2+} ions are indispensable in the enzymatic activities of the tyrosinase family. TYR, TYRP1, and TYRP2 share a signaling peptide-like domain, a cysteine-rich region, a single transmembrane domain at the C-termini, and residues for coordinating the binding of the two metal ions. TYR contains two Cu^{2+} binding sites, and TYRPs hold two Zn^{2+} binding sites [15,16]. The requirement of Cu^{2+} ions for TYR has been clearly demonstrated. Binding of two Cu^{2+} ions and an oxygen molecule in TYR enables the redox properties on oxidation states of monooxygenase and oxidase activities [15]. While TYR requires Cu^{2+} , TYRP2 tautomerase activity requires Zn^{2+} [42]. The binding of metal ions to TYRP1 is still controversial. TYRP1 contains Zn^{2+} binding sites

but biochemical experiments have failed to prove the direct binding of Zn^{2+} [43]. Moreover, mouse and human TYRP1 seem to exhibit different enzymatic properties [16]. Nevertheless, both Cu^{2+} and Zn^{2+} are bona fide cofactors of enzymatic reactions in melanosomal tyrosinase family.

The Cu^{2+} ion in melanosomes is supplied by copper-transporting ATPase 1 (ATP7A), which is translocated from the trans-Golgi network to melanosomal membranes (Fig. 3) [44]. Deficiency of Cu^{2+} by ATP7A malfunction causes Menkes disease, an X-linked multisystemic lethal disorder of Cu^{2+} metabolism [45–47].

Transport of Zn^{2+} in melanosomes is still unclear. Members of the SLC30 family are known as organellar zinc transporters and presumably trafficked from the trans-Golgi network [48]. ZnT2 (SLC30A2) is found in lysosome and critical for lysosomal acidification [49]. It is possible that ZnT2 expresses and supplies Zn^{2+} in melanosomes, but this hypothesis needs to be verified.

5.3. Ca^{2+}

In premelanosomes, Ca^{2+} is necessary for the activity of furin-like protease, an enzyme that cleaves PMEL in the premelanosomes during fibril formation [50]. In stages III–IV melanosomes, Ca^{2+} might be one of the coupling ions for pH modulation. The role of Ca^{2+} is not limited to melanogenesis in melanosomes but is also involved in the signaling responses between melanosomes and melanocytes. Ca^{2+} is known to be a secondary messenger that contributes to signaling pathways and membrane voltage. In non-melanocyte cells, intracellular Ca^{2+} is stored in organelles such as endoplasmic reticulum, mitochondria and lysosome [51]. Melanosome is found to be another organellar Ca^{2+} store in melanocytes due to the high accumulation of Ca^{2+} in melanosomes and properties of Ca^{2+} binding to melanin [52–54]. The enriched Ca^{2+} in melanosomes is released by stimulants such as caffeine and IP_3 [53]. The α -MSH pathway, for instance, is a Ca^{2+} response mechanism for TYR expression [55]. These results support the significance of melanosomal Ca^{2+} in Ca^{2+} -mediated signaling pathways and Ca^{2+} homeostasis between melanosomes and melanocytes, which may be involved in melanogenesis.

Still, the mechanism of Ca^{2+} storage and transport are poorly understood in melanosomes. Ca^{2+} pumps such as SERCA-type calcium pumps (sarco/endoplasmic reticulum calcium ATPase) is a canonical pathway for intracellular Ca^{2+} storage [56]. Ca^{2+} accumulation in melanosomes may be the result of a calcium pump because high Ca^{2+} uptake is observed in the purified melanosomes [53].

As for the Ca^{2+} efflux mechanism, TPC2 is the main contributor (Table 1). TPC2 is identified as the nicotinic acid adenine dinucleotide phosphate (NAADP)-sensitive Ca^{2+} release channel in lysosomes [57–59]. In melanosomes, TPC2 regulates the pH balance by participating in Ca^{2+} efflux [41,60].

SLC24A5 is thought to be a K^+ -dependent Na^+/Ca^{2+} exchanger based on the conserved sequences of the ion binding residues to other SLC24 members. SLC24A5 undoubtedly plays a role in melanin production, but its subcellular localization is uncertain. SLC24A5 would likely mediate Ca^{2+} transport if expressed in melanosomes [9]. Zhang et al., who found SLC24A5 in mitochondria, predicted the model of Ca^{2+} supplement from mitochondria to melanosome via SLC24A5 function in mitochondria-melanosome contact region [61].

6. Ion transport proteins in melanogenesis

Due to the significance of ions and ion transport proteins in melanogenesis, there is no doubt that impairment of the ion transport system would result in pigmentation disorders such as albinism. Albinism is a congenital disorder defined by a lack of pigmentation (both complete and partial). Two groups of albinism, oculocutaneous albinism (OCA) and ocular albinism (OA), are classified based on the diagnostic phenotypes. OCA, the most common group, describes the abnormal

Table 1
Ion transport proteins in human pigmentation.

Proteins	Substrates	Localization	Genetic disorder	A) Pathogenic mutations ^a B) Polymorphisms ^b	Phenotypes ^c
OCA2/P	Cl ⁻ ?	Melanosome stages III–IV	Type II OCA	A) V443I, A481T, P743L B) R305W, R419Q	A) Skin and hair hypopigmentation, reduced iris and retinal pigments, and ocular defect B) Blue/green/hazel eye colors
SLC45A2/MATP/ AIM1	H ⁺ /sugar co-transport?	Melanosome stages III–IV	Type IV OCA	A) D93N, D157N, G188V, T437A, T440A, A477T B) E272K/K272E, F374L/L374F	A) Light/yellow/white/blue hairs, blue/red/brown/gray eye colors, and some nystagmus. B) Blue/green/hazel/brown eye colors, olive/brown/black skin, black/brown/blond/red hair
SLC24A5/NCKX5	Na ⁺ /Ca ²⁺ and K ⁺ antiport?	TGN Mitochondria (Melanosome?)	Type VI OCA	A) A115E, R174K, S182R, W197X B) T111A/A111T	A) White skin, brown hair, brown iris, and underdeveloped macula B) Light skin pigmentation
TPC2/TPCN2	Ca ²⁺ or Na ⁺ ?	Melanosome stages III–IV *Multiple organelles	–	B) G734E, M484L	B) Blond hair
ATP7A/MNK	Cu ²⁺	TGN Melanosome stages III–IV	Menkes disease	A) E628V, S653Y, C1002F	A) Broad phenotypes. Severe defect leads to death. Classical phenotypes: growth failure, Kinky hair, nervous system deterioration
V-ATPase	H ⁺	Melanosome (all stages) *Multiple organelles	–	–	–

OCA, oculocutaneous albinism; TGN, trans-Golgi network.

^a Examples of pathogenic mutations.

^b Examples of non-pathogenic polymorphisms.

^c Examples of phenotypes which are corresponded to either pathogenic mutations (A) or non-pathogenic polymorphism (B).

formation of melanin in eyes, skin, and hair, while OA is the abnormality limited to eyes. OCA is an autosomal recessive disorder caused by the impairment of genes involved in melanogenesis. OCA is subdivided into seven types (type I–VII OCA) [4]. Type I and III OCA are caused by mutations of *TYR* and *TYRP1*, respectively. Type II, IV and VI OCA are caused by mutations of ion transport proteins *OCA2*, *SLC45A2*, and *SLC24A5*, respectively (Table 1). The defect of *ATP7A* does not cause albinism but causes Menkes disease. Symptoms of the Menkes patients vary but include abnormalities in hair and skin [62]. *TPC2* defect leads to abnormalities of melanin production and pigmentation [63]; however, their corresponding disease was not reported (Table 1). Here, we summarize the current knowledge of the ion transport proteins—their physical properties, biochemical functions, physiological roles and pathological effects in melanosomes.

6.1. OCA2/P

6.1.1. Functional aspect

OCA2 (also known as *pink-eyed dilution/P*; human gene: NM_000275) gene was first identified in mouse and human as the *P* locus responsible for pink-eyed dilution [64,65]. At the same time, Ramsay et al. identified the loci at the close region of *P* locus as the associated loci for type II OCA [66]. Later, the two loci were verified to be the same gene named *OCA2/P*, which is also typically related to Prader-Willi and Angelman syndrome, a disorder resulting from partial deletion of chromosome 15q11-q13 [67]. *OCA2* (838 amino acid residues) is predicted to contain 12 transmembrane domains [40,67]. *OCA2* mRNA is expressed in the eyes, skin, and brain (The Human Protein Atlas project: <http://www.proteinatlas.org>, last update March 2020). At subcellular localization, *OCA2* protein is specifically expressed in mature (stages III–IV) melanosomes [68]. Like *TYR* and *TYRPs*, *OCA2* contains an acidic dileucine motif and colocalizes with *BLOC-1* (a cargo-specific sorting protein for *TYRP1*) for sorting from Golgi apparatus to early endosomes and targets to melanosomes [23].

By utilizing immortal *OCA2* mutant and knockout cell models, several studies showed the role of *OCA2* as a positive regulator of pH neutralization and melanogenesis promotion (Fig. 3) [28,29,34,40,69,70]. The pH regulation by *OCA2* targets V-ATPase as observed in the rescue of *TYR* function after V-ATPase inhibition in *OCA2*-knockout melanocytes [28,29,34,69,70]. Besides pH regulation,

OCA2 likely facilitates *TYR* trafficking from ER/Golgi network to melanosomes. The *OCA2*-knockout melanocytes show some *TYR* retaining on ER/Golgi network, and the melanosomal re-localization of *TYR* could be rescued by pH modulation [69–72]. All data point to the *dual roles* of *OCA2*-dependent pH regulation—for both *TYR* trafficking and *TYR* activities.

OCA2 is predicted to be a member of the Mg²⁺/citrate or Na⁺/citrate transporter family (SLC13 family) based on amino acid sequence similarities [73]. However, *OCA2* has not been classified into any existing SLC families [74]. Previous studies indicated that *OCA2* is not a tyrosine transporter [75]. Bellono et al. demonstrated that *OCA2* mediates Cl⁻-selective anion conductance by using the patch clamp method with *OCA2*-knockdown melanosomes dissected from *Oa1*^{-/-} melanocyte (melanocytes with enlarged melanosomes). *OCA2* induces large outwardly rectifying current with a negative charge of Cl⁻. This Cl⁻ conductance is essential for maintaining neutral pH for melanosomes. In the addition, electrophysiological property has been characterized in the endolysosome of the recombinant *OCA2*-expressing AD-293 cells suggesting that *OCA2* is an electrodiffusion anion channel [40].

6.1.2. Mutations and polymorphisms

Despite the limited knowledge of *OCA2* function, mutations of *OCA2* in humans and animals have been intensively identified. *OCA2* is a causative gene for type II OCA (MIM#203200), which is the most common type of OCA worldwide. Hundreds of mutations are identified in humans (Albinism Database: <http://www.ifpcs.org>, last update September 2009; The Human Gene Mutation Database: <http://www.hgmd.cf.ac.uk>, last update April 2019). The pathogenic phenotypes include hypopigmentation of skin and hair, reduced iris and retinal pigments, and ocular defect (Lewis RA. Gene Reviews, last update August 2012: <http://www.ncbi.nlm.nih.gov/books/NBK1343/>). At the cellular level, the patient has small melanocytes, immature melanosomes, and no or little melanin production. Examples of pathogenic mutations are V443I, P743L, and A481T. Patients with V443I and P743L double mutations develop severe phenotypes of type II OCA and Prader-Willi syndrome [76]. A481T, a mutation associated with mild-symptom phenotypes, is commonly found in Caucasians as well as in East Asians [76–78]. Polymorphisms of *OCA2* give rise to diverse variations of eyes, hair, and skin colors such as blue eyes (Table 1) [79,80].

6.2. SLC45A2/MATP/AIM1

6.2.1. Functional aspect

Before discovering *SLC45A2* as a causative gene for albinism, *SLC45A2* (*MATP/AIM1*; human gene NM_016180) was identified as a gene named “*Absent In Melanoma*” associated to tumor suppression in melanoma model [81,82]. In 2001, Newton et al. discovered *SLC45A2* as a responsible gene for human type IV OCA (OCA4) and mouse “*underwhite*” [83]. At the same time, Fukamachi et al. found that *SLC45A2* is a gene for allele *b*, a well-known hypopigmentation allele in medaka [84]. *SLC45A2* (530 amino acid residues), predicted to contain 12-transmembrane domains, is a member of H^+ /sugar cotransporter family (SLC45 family). *SLC45* mRNA expresses in eyes, skin, placenta, liver, and kidney (The Human Protein Atlas project: <http://www.proteinatlas.org>, last update March 2020) [82]. In melanocytes, *SLC45A2* is expressed in stages III–IV melanosomes [37].

The function of *SLC45A2* in melanosomes is still largely unclear. Recombinantly expressed mouse *SLC45A2* mediates sugar transport at the plasma membrane of yeast cells, with the optimal function at a wide pH range. The sucrose transport is H^+ dependent, supporting the property of SLC45 as a H^+ -coupled sugar transporter [36]. A rice-homolog protein also transports sugar in the plasma membrane of oocytes [85]. Although *SLC45A2* and the ortholog are proposed to be sugar transporters, the activities were observed at the plasma membrane. Thus, physiological transport function and kinetic property of *SLC45A2*, expressed in melanosomes, has not been demonstrated.

The role of *SLC45A2* in melanosomes is well defined. Costin et al. showed that *SLC45A2* promotes TYR trafficking from the trans-Golgi network to melanosomes. The defect of *SLC45A2* (*underwhite*) disrupts the TYR secretion process [86]. Dooley et al. describes that *SLC45A2* regulates pH and melanogenesis. Albino zebrafish has a *SLC45A2* mutation and a defect of TYR function. The phenotypes can be rescued by inhibition of V-ATPase or *SLC45A2* RNA reinjection [35]. Bin et al. supports the role of *SLC45A2* in pH regulation. The knockdown of *SLC45A2* does not affect melanosomal morphology but induces melanosomal acidification that interrupts TYR activity [37].

The role of *SLC45A2* in melanogenesis is similar to that of *OCA2*—to promote TYR trafficking and positively regulate pH neutralization for TYR activity. Although both aspects could be independent, the role of *SLC45A2* in the pH regulation is certain. Based on the current information, *SLC45A2* is predicted to efflux H^+ from melanosomes (Fig. 3) [36,37,85]. If so, the H^+ efflux by *SLC45A2* reduces melanosomal H^+ concentration driven by V-ATPase, thereby neutralizing the melanosomal pH. Because *SLC45A2* likely transports sugar, a significant agent for osmotic concentration, *SLC45A2* may control both pH and osmolarity [87].

SLC45A2 does not only play a role in melanogenesis, but also acts as a suppressor of cancer invasion. Because *SLC45A2* was discovered to be a deleted gene in melanoma, *SLC45A2* has been suggested to play a role in cancer prevention or suppression. Haffner et al. showed that *SLC45A2* interacts with actin cytoskeleton to prevent actin remodeling, and then suppresses the pro-invasion and migration of the benign tumor [88]. The role of *SLC45A2* in cancer could be related to its role in melanosomes.

6.2.2. Mutations and polymorphisms

Type IV OCA (MIM#606574) is an autosomal recessive hypopigmentary disorder that disrupts pigmentation in the skin, hair and eyes. Type IV OCA by *SLC45A2* mutation has been reported to be another common form, especially in Japanese patients [89]. The most frequent mutations are D93N, D157N, and G188V, which result in light/yellow/white/blue hair, blue/red/brown/gray eye color, and some nystagmus. A477V causes leucism in lions and tigers, and the mutation (A477T) has been reported once in humans [90,91]. We constructed a 3D structure model of the *SLC45A2* by using lactose permease (LacY; PDB No. 5GX8) as a template (Fig. 4) [92]. The model




Fig. 4. 3D structural model of human *SLC45A2*.

Structural model of human *SLC45A2* is built by SWISS-MODEL using Lac Y as template: left, side view; right, top view (neglect bottom parts of the structure). *SLC45A2* contains 12 transmembrane domains (TM numbers are indicated in the top view picture). The model conserves the structural fold of the major facilitator superfamily in which TM1–6 and TM7–12 are arranged in two-fold pseudosymmetry. Some residues at TM6–7 loop are omitted in the modeling for the best fit. The substrate binding sites are predicted to be at the core center of TM1, 4, 5 and TM7, 10, 11 (magenta area), whereas the H^+ recognition sites are at TM7, 9, 10 (green area). Residues corresponding to type IV OCA mutations and polymorphisms are shown in ball-and-stick. Residues D157 and G188 are located at the area of substrate binding sites.

contains 12 transmembrane domains (TM) with the conserved structural fold of the major facilitator superfamily (MFS). Two bundles, (TM 1, 4, 5) and (TM 7, 10, 11), are arranged in pseudosymmetry and form a presumable substrate binding site, while residues on TM 7, 9 and 10 may be involved in proton coupling and transfer. In the model, residues D157 and G188 are located in the middle of TM 4 and 5, respectively, suggesting that they are key residues for substrate binding (Fig. 4).

Polymorphisms of *SLC45A2* generate different degrees of melanosomal size, shape, melanin content and melanosomal maturity, resulting in hair and skin color variety. E272K/K272E and L374F/F374L are associated with population differences in human skin colors, which may be a result of natural selection or adaptation to ultraviolet radiation [93]. Both E272 and L374 are located outside of the proposed H^+ and substrate binding sites, which may be a reason for the mild symptoms. Currently, more than 50 mutations have been reported in humans (Albinism Database: <http://www.ifpcs.org>, last update September 2009; The Human Gene Mutation Database: <http://www.hgmd.cf.ac.uk>, last update April 2019). The structural model may be beneficial in predicting the severity and pathology of type IV OCA.

6.3. SLC24A5/NCKX5

6.3.1. Functional aspect

SLC24A5 (*NCKX5*, human gene NM_205850) was first identified as a gene susceptible for *golden* (hypopigmentation) phenotype in zebrafish [94]. By next-generation sequencing, *SLC24A5* is found to be a causative gene for type VI OCA (OCA6) [95]. *SLC24A5* mRNA is specifically detected in pigmentation-related tissues (The Human Protein Atlas project: <http://www.proteinatlas.org>, last update March 2020). Malfunction of *SLC24A5* alters the melanin production and results in albino phenotypes (small sized melanosomes, less melanin content, and low pigment granules) in humans as well as animal models [95,96]. *SLC24A5* is detected in the stages III–IV melanosome-enriched fraction by sucrose gradient centrifugation experiments [9]. Subsequently, imaging experiments revealed that *SLC24A5* is presented in the trans-

Golgi network [97,98]. Recently, Zhang et al. demonstrated localization of SLC24A5 both in mitochondria and trans-Golgi network but not in melanosomes [61].

SLC24A5 is the most recently identified member of SLC24 family. Although little is known about SLC24A5, the functional properties of other members are well defined, especially for SLC24A2 (NCKX2) which is important for neuronal function [99]. Ca^{2+} -cation antiporter superfamily is composed of two families, $\text{Na}^+/\text{Ca}^{2+}$ exchanger (NCX, SLC8) and K^+ -dependent $\text{Na}^+/\text{Ca}^{2+}$ exchanger (NCKX, SLC24) families. NCKXs transport 1 Ca^{2+} and 1 K^+ in exchange for 4 Na^+ . NCKXs play physiological roles in Ca^{2+} homeostasis and membrane potential maintenance [99,100].

SLC24A5 is predicted to transport K^+ and Ca^{2+} in exchange with Na^+ like other NCKX members. The transport function of SLC24A5 activates both melanogenesis and melanosome biogenesis implying ion regulation and Ca^{2+} supplementation by SLC24A5 in melanosomes [61,97]. There are three proposed mechanisms for how SLC24A5 supplies the ions to melanosomes based on its subcellular localization. The first possibility is that SLC24A5 in trans-Golgi network plays a role in pH regulation by functional coupling with NHE7 and V-ATPase. This functional coupling may ensure the TYR maturation and proper trafficking of TYR from trans-Golgi network to melanosomes [97]. Another possibility is based on SLC24A5 localization in melanosomes as mentioned in the previous section; SLC24A5 supplies Ca^{2+} to promote PMEL polymerization and maintain Ca^{2+} homeostasis as well as membrane potential in melanosomes [94]. The third possibility is derived from the localization of SLC24A5 in mitochondria. SLC24A5 may transfer Ca^{2+} from mitochondria to melanosome via “mitochondrion-melanosome contact” [61,101].

6.3.2. Mutations and polymorphisms

The defect of SLC24A5 causes type VI OCA (MIM#113750), an autosomal recessive albinism. Type VI OCA patients have mild symptoms compared to other OCA. The patients have hypopigmentation, reduced visual acuity, nystagmus, hair color ranging from platinum blond to light brown, and green or blue eye color. Pathogenic mutations are, for examples, A115E, R174K, S182R, and W197X. However, these patients have non-syndromic OCA [95,102]. Polymorphism of SLC24A5 is related to regions. A111 is found to be associated with light skin pigmentation among European and East Asians. The variation is approximately 20–40% of European-African difference in skin melanin index. T111 is commonly found in Europeans while A111 is common in Africans and East Asians [94].

Presumably, the 3D structures of NCKXs are conserved with that of NCXs [103]. The crystal structure of the archaeobacterial ortholog (NCX_Mj) represents a structure composed of 10 transmembrane domains in 5–5 inverted repeats and $\text{Na}^+/\text{Ca}^{2+}$ binding sites located in the middle of TM2–3 and TM7–8 (see also Fig. 5) [104]. Models of eukaryotic NCXs and NCKXs show a set of 10 TMs similar to NCX_Mj, and two additional regions—(1) N-terminal region, which contains a single transmembrane domain (called TM0) and a signal peptide sequence (SPase cleavage site) between TM0 and TM1, may be cleft out; and (2) large cytosolic regulatory f-loop containing two Ca^{2+} binding domains (~500 amino acids) between TM5 and TM6 which functions as a Ca^{2+} -sensing domain [100,103]. We, therefore, constructed a 3D structural model of SLC24A5 using the structure of NCX_Mj (PDB No. 3V5U) as the template. We aligned amino acid sequences of SLC24A5 to NCX_Mj, and other human NCKXs. The feasible N-terminal region and cytosolic f-loop are omitted from the model. The model shows 10 TM domains which are well aligned to NCX_Mj structure (Fig. 5).

We mapped the mutation residues (A111, A115, R174, S182, and W197) to the SLC24A5 model (Fig. 5). Notably, none of them correspond to substrate binding sites. A111, A115, R174, and S182 are located on TM4 and TM6 which are at the outer array of the core substrate binding TMs (TM2–3 and TM7–8). W197 is located at the top of TM7 but far away from the center. We suggest that these residues are




Fig. 5. 3D structural model of human SLC24A5.

Structural model of human SLC24A5 is predicted based on the structure of archaeobacterial ortholog NCX_Mj; left, side view; right, top view. Seventy amino acid residues at N-terminus and residues 212–314 located between TM 5–6 covering the signaling peptides and f-loop, respectively, are omitted from the modeling for the best fit. The model contains 10 transmembrane domains in which TM1–5 and TM6–10 align in two-fold inverted repeats. Apparent f-loop (dash line) is manually drawn to connect TM5 and TM6. Amino acid sequence alignment of SLC24A1–SLC24A5 and NCX_Mj demonstrated that all ion binding sites in NCX_Mj are conserved among all SLC24 members. The predicted ion binding sites of SLC24A5 are A46, S49, S50 and E53 in TM2; S76, and, N80 in TM3; A204, T207, S208, and D211 in TM7; and S234, and D238 in TM8 (cyan area). Residues corresponding to type VI OCA mutations (A115, R174, and S182) and polymorphisms (A111) are shown in ball-and-stick. All mutation residues locate far away from the putative ion binding site and indeed the phenotypes of type VI OCA is considered as non-severe syndrome.

not involved with the substrate recognition; therefore, the mutation may not severely cause the loss of transport activity. The position of mutation residues likely explains why the patients with A115E, R174K, S182R, and W197X exhibit mild symptoms and A111T only causes variety of hair and skin colors.

6.4. TPC2/TPCN2

6.4.1. Functional aspect

TPC2 (TPCN2, human gene NM_139075) gene was cloned based on the sequence similarity to TPC1, another member of two-pore channels (TPC) [59]. TPC2 (752 amino acids) is an organellar transporter localized in endosome, endolysosome, lysosome and melanosome and ubiquitously expressed in most tissues [41,58,59]. The 3D cryo-EM structure of TPC2 reveals the dimerization of TPC2 forming a tetramer-like voltage-sensing channel. Each subunit comprises two sets of homologous 6-TM domains. The voltage sensing domain is from TM1–4 helices. TM5 and TM6 from each set of protomers assemble to form a central ion conduction pore [105]. Unlike TPC1 and TPC3, TPC2 functions as a voltage-independent cation channel, meaning that the channel is opened in response only to the binding of its ligands, independently from membrane potential [105–107]. The opened channel allows the cation (Na^+ or Ca^{2+}) to flow across from lumen to cytosol (cation conductance).

The TPC2-regulating pathway in non-pigmented cells has been studied quite intensively, although the recognized ligands and ionic substrates of TPC2 are still controversial. TPC2 is found to be a receptor for either nicotinic acid adenine dinucleotide phosphate (NAADP) or $\text{PI}(3,5)\text{P}_2$ or both [108,109]. Both NAADP and $\text{PI}(3,5)\text{P}_2$ are intracellular second messengers in response to various stimuli. NAADP-sensing TPC2 mediates Ca^{2+} release in lysosome and endolysosome [58,59,110–114]. $\text{PI}(3,5)\text{P}_2$ -dependent TPC activation induces Na^+ release [105,115–118]. Despite the difference of stimuli and responsive ions, most studies demonstrate the common role of TPC2 in lysosomal

stability and pH maintenance, implying the significance of TPC2 on lysosomal protein functions. Malfunction of TPC2 results in impairment of lysosomal acidification. Upstream molecules that regulate TPC2 are, for example, VEGF, mTOR, p38, and MAPK [113,119,120]. TPC2 has a wide effect on cellular activities such as cell invasion, autophagy, muscle contraction, and angiogenesis [112,118,119,121]. Notably, TPC2 is a target for Ebola virus and MERS-CoV (Middle East respiratory syndrome coronavirus) infectivity and treatment [122–124].

Both *TPC1* and *TPC2* were initially discovered as associated genes for genetic pigmentation in Europeans, but only TPC2 has been confirmed to exist in melanosomes [41,125,126]. Studies in melanosomes bring a similar debate to those in non-melanocyte's lysosomes about preferable stimulants and ions of TPC2. By using oocyte and melanocyte models, Lin et al. and Ambrosio et al. showed that TPC2 mediates Ca^{2+} release in response to NAADP [41,60]. Meanwhile, Bellono et al. demonstrated the $\text{PI}(3,5)\text{P}_2$ activates TPC2-mediated Na^+ -selective conductance [126]. The response to $\text{PI}(3,5)\text{P}_2$ is further observed in a TPC2-expressing endolysosome models [63]. Nevertheless, loss of TPC2 clearly affects melanosomal pH and size, and melanin production. Likewise, TPC2 plays a role in pH maintenance by acting as a negative regulator for melanin production and pH neutralization (TPC2 promotes acidic pH) [41,126]. It is postulated that TPC2 generates membrane voltage (membrane potential) by the positive conductance, thus, controlling the function of V-ATPase for H^+ influx. The combinational function of the negative regulator TPC2 and the positive regulator OCA2 is also proposed to control melanosomal pH [126]. The anion conductance by OCA2 could be counterbalanced with the cation conductance by TPC2 in order to modulate V-ATPase function thereby maintaining ion and pH homeostasis inside the melanosomes (Fig. 3).

6.4.2. Mutations and polymorphism

TPC2 has not been reported to be associated with albinism, however, has been associated in the genetic colors and some pigmentation defect in the European nations. Genome-wide association studies (GWAS) found that *TPC2* mutations in Icelandic and Dutch individuals are linked to hair color, freckles, and degrees of skin sensitivity to UV radiation. Residues G734E and M484L are significantly associated with blond hair over brown hair (Table 1) [125].

6.5. ATP7A/MNK

6.5.1. Functional aspect

ATP7A (*MNK*, human gene NM_000052), located on the X-chromosome, encodes 1500 amino acids for a P-type ATPase. *ATP7A* is a primary active transport protein that utilizes ATP hydrolysis to mediate Cu^{2+} transport out of the cytosol. *ATP7A* is ubiquitously expressed in most tissues and plays a central role in controlling Cu^{2+} balance in the cells. Cu^{2+} is an essential cofactor for enzymatic functions, however, excessive amounts of Cu^{2+} lead to tissue toxicity such as liver diseases and neurological defects [62,127,128]. Accordingly, cells need to restrict cellular Cu^{2+} homeostasis, and thus, *ATP7A* is critical. *ATP7A* has dual functions; in non-pigmented cells, *ATP7A* is trafficked between plasma membrane and trans-Golgi network via exocytosis and endocytosis [129]. Under normal conditions, *ATP7A* resides in the trans-Golgi network and supplies Cu^{2+} to the Cu^{2+} -dependent proteins (so called cuproproteins) such as cytochrome C oxidase and superoxide dismutase [130,131]. In the presence of an exceeding amount of Cu^{2+} , *ATP7A* is translocated to the plasma membrane and transports Cu^{2+} out of the cell. When Cu^{2+} returns to physiological level, *ATP7A* is relocated back to trans-Golgi network [128,132–134]. At the blood-brain barrier, *ATP7A* is trafficked to the basolateral membrane to promote Cu^{2+} delivery to the brain. *ATP7A* plays important roles in neuron activation, angiotensin-II-associated hypertension, cisplatin resistance and hepatic Cu^{2+} mobilization [62].

The 3D structure of *ATP7A* by homology modeling revealed the conserved core structure of P-type ATPases which is composed of

transmembrane (M) domain assembled from MA, MB and TM1–6 helices, actuator (A) domain at TM2–3 loop, and phosphorylation (P) and nucleotide (N) domains located at TM4–5 loop [135]. The Cu^{2+} binding sites are located inside the M domain. All members of copper-ATPases contain N-terminal 6 heavy metal binding domains, which may be involved in autoinhibition and trafficking rather than Cu^{2+} transport [135]. Importantly, *ATP7A* contains a luminal loop located between MA and MB called HM loop (His- and Met-rich loop) which is absent in *ATP7B*, another copper-transporting ATPase [135,136]. HM loop likely mimics the function of metallochaperones by serving itself as a platform for Cu^{2+} transferring from *ATP7A* to cuproproteins directly without specific chaperones. His and Met in HM loop are potential copper ligands, and they undergo His-to-Met ligand switching via His protonation in different pH. This pH-sensitive HM loop thereby accommodates conformational flexibility allowing Cu^{2+} transfer to different cuproproteins that exhibit optimal functions at different pH, e.g. metalation to TYR in neutral pH and PHM (peptidylglycine alpha-hydroxylating monooxygenase) in acidic pH [136].

In melanocyte, *ATP7A* is the transporter that supplies Cu^{2+} for TYR function. *ATP7A* is translocated from trans-Golgi network to melanosomes via BLOC-1 containing cargo which also sorts TYRP1 and OCA2 [22]. As described, Cu^{2+} is an indispensable cofactor for TYR function. Previous studies demonstrated that TYR exhibits as Cu^{2+} -bound form since it is located in trans-Golgi network (prior to translocation to the melanosome), and Cu^{2+} is continuously supplied to TYR to ensure TYR function in stages III–IV melanosomes [137]. Setty et al. confirmed that melanosomal *ATP7A* transports Cu^{2+} from cytosol to the lumen, thereby supplying Cu^{2+} to TYR during melanosome maturation (Fig. 3) [22]. One question remains to be addressed: how does TYR get Cu^{2+} loading during its localization in trans-Golgi network? *ATP7A* may be involved in this action as well because *ATP7A* and TYR coexist in the trans-Golgi network. Additionally, *ATP7A* is active in broad-range pH due to its H^+ -controlling switch in HM loop [136]. Taken together, *ATP7A* may be functional to continuously supply Cu^{2+} to TYR at both trans-Golgi networks and melanosomes.

6.5.2. Mutations and polymorphism

Menkes disease (MIM#309400) and Occipital Horn syndrome (OHS) (MIM#304150) are the X-linked disorders of copper deficiency, which is caused by *ATP7A* [45–47]. Because *ATP7A* is located on the X-chromosome, the vast majority of Menkes disease patients are male. Since *ATP7A* is ubiquitously expressed and Cu^{2+} has wide functionality, the patients have various degrees of symptoms ranging from mild to death clinical syndromes [62,138,139]. Complete disrupting the protein function (immature protein or deletion) may lead to childhood fatality [140]. The *classical form* phenotype is characterized by progressive neurological degeneration, osteoporosis, connective tissue defect, sparse hypopigmented hair, hypopigmented skin, and retinal degeneration. The *milder form* is termed OHS, which has connective tissue abnormalities [62]. At present, more than 100 mutations have been reported.

7. Conclusion and future direction

This review summarizes the current knowledge of the ions and ion transport proteins in melanogenesis. We describe both the functional properties of ion transport proteins and the roles of the ion substrates. All ion transport proteins unite their unique functions to grant the central goal—to promote TYR function. TYR is the key enzyme for melanogenesis. TYR function is solely dependent on neutral pH and the existence of Cu^{2+} as a cofactor. All ion transport proteins play significant roles in this respect. *ATP7A* simply transports Cu^{2+} to supply Cu^{2+} to TYR. OCA2, SLC45A2 and TPC2 (perhaps also SLC24A5) are important for pH maintenance. Although the mechanism of pH regulation remains unclear, the goal of the transport proteins is simple—to change the acidic pH in premelanosomes to neutral pH in stages III–IV

melanosomes. To modulate pH, OCA2, SLC45A2, and TPC2 likely need to function together in a so called “combinational function of ion transport proteins”. Based on the present information, we propose the model of combinational function of ion transport proteins for the pH maintenance in stages III–IV melanosomes (Fig. 3).

Existing research provides the key information: (1) Premelanosomes (stages I–II) has acidic pH from the function of V-ATPase, to authorize PMEL function; (2) OCA2, SLC45A2, and TPC2 along with TYR and TYRP1 are trafficked from trans-Golgi to melanosomes at stages II–III; (3) melanosomes at stages III–IV have neutral pH; and (4) TYR functions to produce melanin at neutral pH in melanosomes at stages III–IV. Together, these results suggest that the combination of OCA2, SLC45A2 and TPC2 functions serves as a “switch” for changing melanosomes from stage II to stage III. pH modulation leads to the termination of PMEL fibril formation indicating the end of stage II premelanosomes, and subsequently provides a neutral pH environment for initiation of TYR function indicating the beginning of stage III melanosomes. Additionally, pH appears to be critical for the trafficking of TYR and TYRPs.

The significance of the ion transport proteins in pigmentation is clear, yet the knowledge of their biological function and physiological roles is insufficient. To elucidate the combinational function of multiple ion transport proteins, understanding of the functional properties of each transport protein is crucial. Therefore, further characterization of the transport proteins is a must. Comprehensive studies of protein-protein interactions by mass spectrometry, so-called interactomics, will explain the combinational function of the ion transport proteins. Future genomic and transcriptomic studies may identify more gene candidates and fill the remaining pieces of the Jigsaw puzzle in melanogenesis. The latest advance in structure biology will give us structural information of the ion transport proteins in detail, which may suggest the transport mechanism of proteins. Most importantly, although it is not easy to dissect transport functions of organellar transport proteins, the transport function of the ion transporters can be revealed by using a classical biochemical method, the cell-free transport assay with proteoliposomes, purified protein-reconstituted liposomes as shown by Moriyama or others [141,142]. Recently, *MFSD12* (major facilitator superfamily domain containing protein 12) was identified as an associated gene in pigmentation in African population by GWAS [143,144]. In addition to the ion transport proteins we described above, *MFSD12* requires characterization of its function and role in melanocytes. The melanosomal transport proteins provide a large number of open questions to us.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We would like to thank Takushi Shimomura and Kazuhiro Abe for critical reading and comments. This work is partly supported by MEXT/JSPS KAKENHI under grant number 19K07373, AMED under grant number JP19bm0704039, and Mochida Memorial Foundation for Medical and Pharmaceutical Research to P.W. and by AMED under grant number JP19gm0810010 to S.N.

References

- [1] C. Wasmeier, A.N. Hume, G. Bolasco, M.C. Seabra, Melanosomes at a glance, *J. Cell Sci.* 121 (2008) 3995–3999, <https://doi.org/10.1242/jcs.040667>.
- [2] J.D. Simon, D.N. Peles, The red and the black, *Acc. Chem. Res.* 43 (2010) 1452–1460, <https://doi.org/10.1021/ar100079y>.
- [3] S. D’Mello, G. Finlay, B. Baguley, M. Askarian-Amiri, Signaling pathways in melanogenesis, *Int. J. Mol. Sci.* 17 (2016) 1144, <https://doi.org/10.3390/ijms17071144>.
- [4] W.J. Pavan, R.A. Sturm, The genetics of human skin and hair pigmentation, *Annu. Rev. Genomics Hum. Genet.* 20 (2019) 41–72, <https://doi.org/10.1146/annurev-genom-083118-015230>.
- [5] L. D’Alba, M.D. Shawkey, Melanosomes: biogenesis, properties, and evolution of an ancient organelle, *Physiol. Rev.* 99 (2019) 1–19, <https://doi.org/10.1152/physrev.00059.2017>.
- [6] M.S. Marks, M.C. Seabra, The melanosome: membrane dynamics in black and white, *Nat. Rev. Mol. Cell Biol.* 2 (2001) 738–748, <https://doi.org/10.1038/35096009>.
- [7] G. Raposo, M.S. Marks, Melanosomes — dark organelles enlighten endosomal membrane transport, *Nat. Rev. Mol. Cell Biol.* 8 (2007) 786–797, <https://doi.org/10.1038/nrm2258>.
- [8] X. Wu, J.A. Hammer, Melanosome transfer: it is best to give and receive, *Curr. Opin. Cell Biol.* 29 (2014) 1–7, <https://doi.org/10.1016/j.cob.2014.02.003>.
- [9] A. Chi, J.C. Valencia, Z.-Z. Hu, H. Watabe, H. Yamaguchi, N.J. Mangini, et al., Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes, *J. Proteome Res.* 5 (2006) 3135–3144, <https://doi.org/10.1021/pr060363j>.
- [10] S.K. Fistorol, P.H. Itin, Disorders of pigmentation, *J. Dtsch. Dermatol. Ges.* (2010) 187–201, <https://doi.org/10.1111/j.1610-0387.2009.07137.x>.
- [11] N.W. Bellono, E.V. Oancea, Ion transport in pigmentation, *Arch. Biochem. Biophys.* 563 (2014) 35–41, <https://doi.org/10.1016/j.abb.2014.06.020>.
- [12] Y.-J. Kim, W. Wu, S.-E. Chun, J.F. Whitacre, C.J. Bettinger, Biologically derived melanin electrodes in aqueous sodium-ion energy storage devices, *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 20912–20917, <https://doi.org/10.1073/pnas.1314345110>.
- [13] A. Samokhvalov, L. Hong, Y. Liu, J. Garguilo, R.J. Nemanich, G.S. Edwards, et al., Oxidation potentials of human eumelanosomes and pheomelanosomes, *Photochem. Photobiol.* 81 (2005) 145–148, <https://doi.org/10.1111/j.1751-1097.2005.tb01533.x>.
- [14] D. Mitra, X. Luo, A. Morgan, J. Wang, M.P. Hoang, J. Lo, et al., An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background, *Nature* 491 (2012) 449–453, <https://doi.org/10.1038/nature11624>.
- [15] F. Solano, On the metal cofactor in the tyrosinase family, *Int. J. Mol. Sci.* 19 (2018) 633, <https://doi.org/10.3390/ijms19020633>.
- [16] X. Lai, H.J. Wichers, M. Soler-Lopez, B.W. Dijkstra, Structure and function of human tyrosinase and tyrosinase-related proteins, *Chem. Eur. J.* 24 (2018) 47–55, <https://doi.org/10.1002/chem.201704410>.
- [17] A. Körner, J. Pawelek, Mammalian tyrosinase catalyzes three reactions in the biosynthesis of melanin, *Science* 217 (1982) 1163–1165, <https://doi.org/10.1126/science.6810464>.
- [18] J.C. García-Borrón, Z. Abdel-Malek, C. Jiménez-Cervantes, MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation, *Pigment Cell Melanoma Res* 27 (2014) 699–720, <https://doi.org/10.1111/pcmr.12257>.
- [19] D. Zhou, K. Ota, C. Nardin, M. Feldman, A. Widman, O. Wind, et al., Mammalian pigmentation is regulated by a distinct cAMP-dependent mechanism that controls melanosome pH, *Sci. Signal.* 11 (2018) eaau7987, <https://doi.org/10.1126/scisignal.aau7987>.
- [20] G. Raposo, D. Tenza, D.M. Murphy, J.F. Berson, M.S. Marks, Distinct protein sorting and localization to premelanosomes, melanosomes, and lysosomes in pigmented melanocytic cells, *J. Cell Biol.* 152 (2001) 809–824, <https://doi.org/10.1083/jcb.152.4.809>.
- [21] B. Watt, G. van Niel, G. Raposo, M.S. Marks, PMEL: a pigment cell-specific model for functional amyloid formation, *Pigment Cell Melanoma Res* 26 (2013) 300–315, <https://doi.org/10.1111/pcmr.12067>.
- [22] S.R.G. Setty, D. Tenza, E.V. Sviderskaya, D.C. Bennett, G. Raposo, M.S. Marks, Cell-specific ATP7A transport sustains copper-dependent tyrosinase activity in melanosomes, *Nature* 454 (2008) 1142–1146, <https://doi.org/10.1038/nature07163>.
- [23] A. Sitarum, M.K. Dennis, R. Chaudhuri, W. De Jesus-Rojas, D. Tenza, S.R.G. Setty, et al., Differential recognition of a dileucine-based sorting signal by AP-1 and AP-3 reveals a requirement for both BLOC-1 and AP-3 in delivery of OCA2 to melanosomes, *Mol. Biol. Cell* 23 (2012) 3178–3192, <https://doi.org/10.1091/mbc.e11-06-0509>.
- [24] A. Slominski, J. Wortsman, P.M. Plonka, K.U. Schallreuter, R. Paus, D.J. Tobin, Hair follicle pigmentation, *J. Invest. Dermatol.* 124 (2005) 13–21, <https://doi.org/10.1111/j.0022-202X.2004.23528.x>.
- [25] H.R. Kaback, Molecular biology and energetics of membrane transport, *J. Cell. Physiol.* 89 (1976) 575–593, <https://doi.org/10.1002/jcp.1040890414>.
- [26] C.M. Pfefferkorn, R.P. McGlinchey, J.C. Lee, Effects of pH on aggregation kinetics of the repeat domain of a functional amyloid, Pmel17, *Proc. Natl. Acad. Sci. U. S. A.* 107 (2010) 21447–21452, <https://doi.org/10.1073/pnas.1006424107>.
- [27] D.N. Dean, J.C. Lee, pH-dependent fibril maturation of a Pmel17 repeat domain isoform revealed by tryptophan fluorescence, *Intrinsic. Disord. Biochim. Biophys. Acta. Proteins Proteom.* 1867 (2019) 961–969, <https://doi.org/10.1016/j.bbapap.2019.01.012>.
- [28] J. Ancans, M.J. Hoogduijn, A.J. Thody, Melanosomal pH, pink locus protein and their roles in melanogenesis, *J. Invest. Dermatol.* 117 (2001) 158–159, <https://doi.org/10.1046/j.0022-202x.2001.01397.x>.
- [29] J. Ancans, D.J. Tobin, M.J. Hoogduijn, N.P. Smit, K. Wakamatsu, A.J. Thody, Melanosomal pH controls rate of melanogenesis, eumelanin/phaeomelanin ratio and melanosome maturation in melanocytes and melanoma cells, *Exp. Cell Res.* 268 (2001) 26–35, <https://doi.org/10.1006/excr.2001.5251>.
- [30] B.B. Fuller, D.T. Spaulding, D.R. Smith, Regulation of the catalytic activity of

- preexisting tyrosinase in Black and Caucasian human melanocyte cell cultures, *Exp. Cell Res.* 262 (2001) 197–208, <https://doi.org/10.1006/excr.2000.5092>.
- [31] S. Ito, N. Suzuki, S. Takebayashi, S. Commo, K. Wakamatsu, Neutral pH and copper ions promote eumelanogenesis after the dopachrome stage, *Pigment Cell Melanoma Res* 26 (2013) 817–825, <https://doi.org/10.1111/pcmr.12137>.
- [32] K. Wakamatsu, A. Nagao, M. Watanabe, K. Nakao, S. Ito, Pheomelanogenesis is promoted at a weakly acidic pH, *Pigment Cell Melanoma Res* 30 (2017) 372–377, <https://doi.org/10.1111/pcmr.12587>.
- [33] H. Tabata, N. Kawamura, G.-H. Sun-Wada, Y. Wada, Vacuolar-type H⁺-ATPase with the a3 isoform is the proton pump on premature melanosomes, *Cell Tissue Res.* 332 (2008) 447–460, <https://doi.org/10.1007/s00441-008-0597-5>.
- [34] P. Manga, S.J. Orlow, Inverse correlation between pink-eyed dilution protein expression and induction of melanogenesis by Bafilomycin A1, *Pigment Cell Res.* 14 (2001) 362–367, <https://doi.org/10.1034/j.1600-0749.2001.140508.x>.
- [35] C.M. Dooley, H. Schwarz, K.P. Mueller, A. Mongera, M. Konantz, S.C.F. Neuhaus, et al., SLC45A2 and V-ATPase are regulators of melanosomal pH homeostasis in zebrafish, providing a mechanism for human pigment evolution and disease, *Pigment Cell Melanoma Res* 26 (2012) 205–217, <https://doi.org/10.1111/pcmr.12053>.
- [36] R. Bartölke, J.J. Heinisch, H. Wiczorek, O. Vitavska, Proton-associated sucrose transport of mammalian solute carrier family 45: an analysis in *Saccharomyces cerevisiae*, *Biochem. J.* 464 (2014) 193–201, <https://doi.org/10.1042/BJ20140572>.
- [37] B.-H. Bin, J. Bhin, S.H. Yang, M. Shin, Y.-J. Nam, D.-H. Choi, et al., Membrane-associated transporter protein (MATP) regulates melanosomal pH and influences tyrosinase activity, *PLoS One* 10 (2015) e0129273, <https://doi.org/10.1371/journal.pone.0129273>.
- [38] E.-R. Nicoli, M.R. Weston, M. Hackbarth, A. Becerril, A. Larson, W.M. Zein, et al., Lysosomal storage and albinism due to effects of a *de novo* *CLCN7* variant on lysosomal acidification, *Am. J. Hum. Genet.* 104 (2019) 1127–1138, <https://doi.org/10.1016/j.ajhg.2019.04.008>.
- [39] D.R. Smith, D.T. Spaulding, H.M. Glenn, B.B. Fuller, The relationship between Na⁺/H⁺ exchanger expression and tyrosinase activity in human melanocytes, *Exp. Cell Res.* 298 (2004) 521–534, <https://doi.org/10.1016/j.yexcr.2004.04.033>.
- [40] N.W. Bellono, I.E. Escobar, A.J. Lefkovich, M.S. Marks, E. Oancea, An intracellular anion channel critical for pigmentation, *eLife* 3 (2014) e04543, <https://doi.org/10.7554/eLife.04543>.
- [41] A.L. Ambrosio, J.A. Boyle, A.E. Aradi, K.A. Christian, S.M. Di Pietro, TPC2 controls pigmentation by regulating melanosome pH and size, *Proc. Natl. Acad. Sci. U. S. A.* 113 (2016) 5622–5627, <https://doi.org/10.1073/pnas.1600108113>.
- [42] F. Solano, C. Jiménez-Cervantes, J.H. Martínez-Liarte, J.C. García-Borrón, J.R. Jara, J.A. Lozano, Molecular mechanism for catalysis by a new zinc-enzyme, dopachrome tautomerase, *Biochem. J.* 313 (1996) 447–453, <https://doi.org/10.1042/bj3130447>.
- [43] M. Furumura, F. Solano, N. Matsunaga, C. Sakai, R.A. Spritz, V.J. Hearing, Metal ligand-binding specificities of the tyrosinase-related proteins, *Biochem. Biophys. Res. Commun.* 242 (1998) 579–585, <https://doi.org/10.1006/bbrc.1997.8007>.
- [44] Y. Wang, V. Hodgkinson, S. Zhu, G.A. Weisman, M.J. Petris, Advances in the understanding of mammalian copper transporters, *Adv. Nutr.* 2 (2011) 129–137, <https://doi.org/10.3945/an.110.000273>.
- [45] C. Vulpe, B. Levinson, S. Whitney, S. Packman, J. Gitschier, Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase, *Nat. Genet.* 3 (1993) 7–13, <https://doi.org/10.1038/ng0193-7>.
- [46] J. Chelly, Z. Tümer, T. Tonnesen, A. Petterson, Y. Ishikawa-Brush, N. Tommerup, et al., Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein, *Nat. Genet.* 3 (1993) 14–19, <https://doi.org/10.1038/ng0193-14>.
- [47] J.F. Mercer, J. Livingston, B. Hall, J.A. Paynter, C. Begy, S. Chandrasekharappa, et al., Isolation of a partial candidate gene for Menkes disease by positional cloning, *Nat. Genet.* 3 (1993) 20–25, <https://doi.org/10.1038/ng0193-20>.
- [48] R.D. Palmiter, L. Huang, Efflux and compartmentalization of zinc by members of the SLC30 family of solute carriers, *Pflugers Arch.* 447 (2004) 744–751, <https://doi.org/10.1007/s00424-003-1070-7>.
- [49] O.C. Rivera, S.R. Hennigar, S.L. Kelleher, ZnT2 is critical for lysosome acidification and biogenesis during mammary gland involution, *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 315 (2018) R323–R335, <https://doi.org/10.1152/ajpregu.00444.2017>.
- [50] G. Thomas, Furin at the cutting edge: from protein traffic to embryogenesis and disease, *Nat. Rev. Mol. Cell Biol.* 3 (2002) 753–766, <https://doi.org/10.1038/nrm934>.
- [51] A. Raffaello, C. Mammucari, G. Gherardi, R. Rizzuto, Calcium at the center of cell signaling: interplay between endoplasmic reticulum, mitochondria, and lysosomes, *Trends Biochem. Sci.* 41 (2016) 1035–1049, <https://doi.org/10.1016/j.tibs.2016.09.001>.
- [52] U.C. Dräger, Calcium binding in pigmented and albino eyes, *Proc. Natl. Acad. Sci. U. S. A.* 82 (1985) 6716–6720, <https://doi.org/10.1073/pnas.82.19.6716>.
- [53] R. Salceda, G. Sánchez-Chávez, Calcium uptake, release and ryanodine binding in melanosomes from retinal pigment epithelium, *Cell Calcium* 27 (2000) 223–229, <https://doi.org/10.1054/ceca.2000.0111>.
- [54] M.J. Hoogduijn, N.P. Smit, A. Van Der Laarse, A.F. Van Nieuwpoort, J.M. Wood, A.J. Thody, Melanin has a role in Ca²⁺ homeostasis in human melanocytes, *Pigment Cell Res.* 16 (2003) 127–132, <https://doi.org/10.1034/j.1600-0749.2003.00018.x>.
- [55] J.A. Buffey, M. Edgcombe, S.M. Neil, Calcium plays a complex role in the regulation of melanogenesis in murine B16 melanoma cells, *Pigment Cell Res.* 6 (1993) 385–393, <https://doi.org/10.1111/j.1600-0749.1993.tb00620.x>.
- [56] E. Strehler, M. Treiman, Calcium pumps of plasma membrane and cell interior, *Curr. Mol. Med.* 4 (2004) 323–335, <https://doi.org/10.2174/1566524043360735>.
- [57] A. Galione, A.M. Evans, J. Ma, J. Parrington, A. Arredouani, X. Cheng, et al., The acid test: the discovery of two-pore channels (TPCs) as NAADP-gated endolysosomal Ca²⁺ release channels, *Pflug. Arch. - Eur. J. Physiol.* 458 (2009) 869–876, <https://doi.org/10.1007/s00424-009-0682-y>.
- [58] P.J. Calcraft, M. Ruas, Z. Pan, X. Cheng, A. Arredouani, X. Hao, et al., NAADP mobilizes calcium from acidic organelles through two-pore channels, *Nature* 459 (2009) 596–600, <https://doi.org/10.1038/nature08030>.
- [59] X. Zong, M. Schieder, H. Cuny, S. Fenske, C. Gruner, K. Rötzer, et al., The two-pore channel TPCN2 mediates NAADP-dependent Ca²⁺-release from lysosomal stores, *Pflug. Arch. - Eur. J. Physiol.* 458 (2009) 891–899, <https://doi.org/10.1007/s00424-009-0690-y>.
- [60] Y. Lin-Moshier, M.V. Keebler, R. Hooper, M.J. Boulware, X. Liu, D. Churamani, et al., The two-pore channel (TPC) interactome unmasks isoform-specific roles for TPCs in endolysosomal morphology and cell pigmentation, *Proc. Natl. Acad. Sci. U. S. A.* 111 (2014) 13087–13092, <https://doi.org/10.1073/pnas.1407004111>.
- [61] Z. Zhang, J. Gong, E.V. Sviderskaya, A. Wei, W. Li, Mitochondrial NCKX5 regulates melanosomal biogenesis and pigment production, *J. Cell Sci.* 132 (2019) jcs232009, <https://doi.org/10.1242/jcs.232009>.
- [62] R. Ojha, A.N. Prasad, Menkes disease: what a multidisciplinary approach can do, *J. Multidiscip. Healthc.* 9 (2016) 371–385, <https://doi.org/10.2147/JMDH.S93454>.
- [63] Y.-K. Chao, Y. Schludi, C.-C. Chen, E. Butz, O.N.P. Nguyen, M. Müller, et al., TPC2 polymorphisms associated with a hair pigmentation phenotype in humans result in gain of channel function by independent mechanisms, *Proc. Natl. Acad. Sci. U. S. A.* 114 (2017) E8595–E8602, <https://doi.org/10.1073/pnas.1705739114>.
- [64] M. Brilliant, Y. Gondo, E. Eicher, Direct molecular identification of the mouse pink-eyed unstable mutation by genome scanning, *Science* 252 (1991) 566–569, <https://doi.org/10.1126/science.1673574>.
- [65] J.M. Gardner, Y. Nakatsu, Y. Gondo, S. Lee, M.F. Lyon, R.A. King, et al., The mouse pink-eyed dilution gene: association with human Prader-Willi and Angelman syndromes, *Science* 257 (1992) 1121–1124, <https://doi.org/10.1126/science.257.5073.1121>.
- [66] M. Ramsay, M.-A. Colman, G. Stevens, E. Zwane, J. Kromberg, M. Farrall, The tyrosinase-positive oculocutaneous albinism locus maps to chromosome 15q11.2-q12, *Am. J. Hum. Genet.* 51 (1992) 879–884.
- [67] E.M. Rinchik, S.J. Bultman, B. Horsthemke, S.-T. Lee, K.M. Strunk, R.A. Spritz, et al., A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism, *Nature* 361 (1993) 72–76, <https://doi.org/10.1038/361072a0>.
- [68] S. Park, V.K. Morya, D.H. Nguyen, B.K. Singh, H.-B. Lee, E.-K. Kim, Unrevealing the role of P-protein on melanosome biology and structure, using siRNA-mediated down regulation of OCA2, *Mol. Cell. Biochem.* 403 (2015) 61–71, <https://doi.org/10.1007/s11010-015-2337-y>.
- [69] K. Chen, P. Manga, S.J. Orlow, Pink-eyed dilution protein controls the processing of tyrosinase, *Mol. Biol. Cell* 13 (2002) 1953–1964, <https://doi.org/10.1091/mbc.02-02-0022>.
- [70] K. Chen, L. Minwalla, L. Ni, S.J. Orlow, Correction of defective early tyrosinase processing by bafilomycin A1 and monensin in pink-eyed dilution melanocytes, *Pigment Cell Res.* 17 (2004) 36–42, <https://doi.org/10.1046/j.1600-0749.2003.00106.x>.
- [71] K. Toyofuku, J.C. Valencia, T. Kushimoto, G.-E. Costin, V.M. Virador, W.D. Vieira, et al., The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase, *Pigment Cell Res.* 15 (2002) 217–224, <https://doi.org/10.1034/j.1600-0749.2002.02007.x>.
- [72] L. Ni-Komatsu, S.J. Orlow, Heterologous expression of tyrosinase recapitulates the misprocessing and mistrafficking in oculocutaneous albinism type 2: effects of altering intracellular pH and pink-eyed dilution gene expression, *Exp. Eye Res.* 82 (2006) 519–528, <https://doi.org/10.1016/j.exer.2005.08.013>.
- [73] A.M. Pajor, Molecular properties of the SLC13 family of dicarboxylate and sulfate transporters, *Pflug. Arch. - Eur. J. Physiol.* 451 (2006) 597–605, <https://doi.org/10.1007/s00424-005-1487-2>.
- [74] E. Perland, R. Fredriksson, Classification systems of secondary active transporters, *Trends Pharmacol. Sci.* 38 (2017) 305–315, <https://doi.org/10.1016/j.tips.2016.11.008>.
- [75] W.A. Gahl, B. Potterf, D. Durham-Pierre, M.H. Brilliant, V.J. Hearing, Melanosomal tyrosine transport in normal and pink-eyed dilution murine melanocytes, *Pigment Cell Res.* 8 (1995) 229–233, <https://doi.org/10.1111/j.1600-0749.1995.tb00668.x>.
- [76] S.T. Lee, R.D. Nicholls, S. Bunday, R. Laxova, M. Musarella, R.A. Spritz, Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome polymorphism, *N. Engl. J. Med.* 330 (1994) 529–534, <https://doi.org/10.1056/NEJM199402243300803>.
- [77] T. Suzuki, Y. Miyamura, J. Matsunaga, H. Shimizu, Y. Kawachi, N. Ohyama, et al., Six novel P gene mutations and oculocutaneous albinism type 2 frequency in Japanese albino patients, *J. Invest. Dermatol.* 120 (2003) 781–783, <https://doi.org/10.1046/j.1523-1747.2003.12127.x>.
- [78] I. Yuasa, S. Harihara, F. Jin, H. Nishimukai, Y. Fujihara, Y. Fukumori, et al., Distribution of *OCA2*481Thr* and *OCA2*615Arg*, associated with hypopigmentation, in several additional populations, *Legal Med.* 13 (2011) 215–217, <https://doi.org/10.1016/j.legalmed.2011.04.003>.
- [79] H. Eiberg, J. Troelsen, M. Nielsen, A. Mikkelsen, J. Mengel-From, K.W. Kjaer, et al., Blue eye color in humans may be caused by a perfectly associated founder mutation in a regulatory element located within the *HERC2* gene inhibiting *OCA2* expression, *Hum. Genet.* 123 (2008) 177–187, <https://doi.org/10.1007/s00439-007-0460-x>.

- [80] R.A. Sturm, D.L. Duffy, Z.Z. Zhao, F.P.N. Leite, M.S. Stark, N.K. Hayward, et al., A single SNP in an evolutionary conserved region within intron 86 of the *HERC2* gene determines human blue-brown eye color, *Am. J. Hum. Genet.* 82 (2008) 424–431, <https://doi.org/10.1016/j.ajhg.2007.11.005>.
- [81] J. Trent, E. Stanbridge, H. McBride, E. Meese, G. Casey, D. Araujo, et al., Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6, *Science* 247 (1990) 568–571, <https://doi.org/10.1126/science.2300817>.
- [82] M.E. Ray, G. Wistow, Y.A. Su, P.S. Meltzer, J.M. Trent, *AIM1*, a novel non-lens member of the -crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma, *Proc. Natl. Acad. Sci. U. S. A.* 94 (1997) 3229–3234, <https://doi.org/10.1073/pnas.94.7.3229>.
- [83] J.M. Newton, O. Cohen-Barak, N. Hagiwara, J.M. Gardner, M.T. Davison, R.A. King, et al., Mutations in the human orthologue of the mouse *underwhite* gene (*uw*) underlie a new form of oculocutaneous albinism, OCA4, *Am. J. Hum. Genet.* 69 (2001) 981–988, <https://doi.org/10.1086/324340>.
- [84] S. Fukamachi, A. Shimada, A. Shima, Mutations in the gene encoding B, a novel transporter protein, reduce melanin content in medaka, *Nat. Genet.* 28 (2001) 381–385, <https://doi.org/10.1038/ng584>.
- [85] A. Reinders, J.M. Ward, Investigating polymorphisms in membrane-associated transporter protein SLC45A2, using sucrose transporters as a model, *Mol. Med. Rep.* 12 (2015) 1393–1398, <https://doi.org/10.3892/mmr.2015.3462>.
- [86] G.-E. Costin, J.C. Valencia, W.D. Vieira, M.L. Lamoreux, V.J. Hearing, Tyrosinase processing and intracellular trafficking is disrupted in mouse primary melanocytes carrying the *underwhite* (*uw*) mutation. A model for oculocutaneous albinism (OCA) type 4, *J. Cell Sci.* 116 (2003) 3203–3212, <https://doi.org/10.1242/jcs.00598>.
- [87] B.H. Bin, S. Kim, J. Bhin, T. Lee, E.-G. Cho, The development of sugar-based anti-melanogenic agents, *Int. J. Mol. Sci.* 17 (2016) 583, <https://doi.org/10.3390/ijms17040583>.
- [88] M.C. Haffner, D.M. Esopi, A. Chau, M. Gürel, S. Ghosh, A.M. Vaghiasa, et al., *AIM1* is an actin-binding protein that suppresses cell migration and micrometastatic dissemination, *Nat. Commun.* 8 (2017) 142, <https://doi.org/10.1038/s41467-017-00084-8>.
- [89] K. Inagaki, T. Suzuki, H. Shimizu, N. Ishii, Y. Umezawa, J. Tada, et al., Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan, *Am. J. Hum. Genet.* 74 (2004) 466–471, <https://doi.org/10.1086/382195>.
- [90] U. Rundshagen, C. Zühlke, S. Opitz, E. Schwinger, B. Käsmann-Kellner, Mutations in the *MATP* gene in five German patients affected by oculocutaneous albinism type 4, *Hum. Mutat.* 23 (2004) 106–110, <https://doi.org/10.1002/humu.10311>.
- [91] X. Xu, G.-X. Dong, X.-S. Hu, L. Miao, X.-L. Zhang, D.-L. Zhang, et al., The genetic basis of white tigers, *Curr. Biol.* 23 (2013) 1031–1035, <https://doi.org/10.1016/j.cub.2013.04.054>.
- [92] X. Jiang, I. Smirnova, V. Kasho, J. Wu, K. Hirata, M. Ke, et al., Crystal structure of a LacY-nanobody complex in a periplasmic-open conformation, *Proc. Natl. Acad. Sci. U. S. A.* 113 (2016) 12420–12425, <https://doi.org/10.1073/pnas.1615414113>.
- [93] K. Nakayama, S. Fukamachi, H. Kimura, Y. Koda, A. Soemantri, T. Ishida, Distinctive distribution of *AIM1* polymorphism among major human populations with different skin color, *J. Hum. Genet.* 47 (2002) 92–94, <https://doi.org/10.1007/s100380200007>.
- [94] R.L. Lamason, M.A. Mohideen, J.R. Mest, A.C. Wong, H.L. Norton, M.C. Aros, et al., *SLC24A5*, a putative cation exchanger, affects pigmentation in zebrafish and humans, *Science* 310 (2005) 1782–1786, <https://doi.org/10.1126/science.1116238>.
- [95] A.-H. Wei, D.-J. Zang, Z. Zhang, X.-Z. Liu, X. He, L. Yang, et al., Exome sequencing identifies *SLC24A5* as a candidate gene for nonsyndromic oculocutaneous albinism, *J. Invest. Dermatol.* 133 (2013) 1834–1840, <https://doi.org/10.1038/jid.2013.49>.
- [96] P. Vogel, R.W. Read, R.B. Vance, K.A. Platt, K. Troughton, D.S. Rice, Ocular albinism and hypopigmentation defects in *Slc24a5*^{-/-} mice, *Vet. Pathol.* 45 (2008) 264–279, <https://doi.org/10.1354/vp.45-2-264>.
- [97] R.S. Ginger, S.E. Askew, R.M. Osborne, S. Wilson, D. Ferdinando, T. Dadd, et al., *SLC24A5* encodes a *trans*-Golgi network protein with potassium-dependent sodium-calcium exchange activity that regulates human epidermal melanogenesis, *J. Biol. Chem.* 283 (2008) 5486–5495, <https://doi.org/10.1074/jbc.M707521200>.
- [98] T.P. Rogasevskaia, R.T. Szerencsei, A.H. Jalloul, F. Visser, R.J. Winkfein, P.P.M. Schnetkamp, Cellular localization of the K⁺-dependent Na⁺-Ca²⁺ exchanger NCKX 5 and the role of the cytoplasmic loop in its distribution in pigmented cells, *Pigment Cell Melanoma Res* 32 (2019) 55–67, <https://doi.org/10.1111/pcmr.12723>.
- [99] M.T. Hassan, J. Lytton, Potassium-dependent sodium-calcium exchanger (NCKX) isoforms and neuronal function, *Cell Calcium* 86 (2020) 102135, <https://doi.org/10.1016/j.ceca.2019.102135>.
- [100] P.P.M. Schnetkamp, The *SLC24* gene family of Na⁺/Ca²⁺-K⁺ exchangers: From sight and smell to memory consolidation and skin pigmentation, *Mol. Asp. Med.* 34 (2013) 455–464, <https://doi.org/10.1016/j.mam.2012.07.008>.
- [101] T. Daniele, I. Hurbain, R. Vago, G. Casari, G. Raposo, C. Tacchetti, et al., Mitochondria and melanosomes establish physical contacts modulated by Mfn2 and involved in organelle biogenesis, *Curr. Biol.* 24 (2014) 393–403, <https://doi.org/10.1016/j.cub.2014.01.007>.
- [102] A.H. Jalloul, T.P. Rogasevskaia, R.T. Szerencsei, P.P.M. Schnetkamp, A functional study of mutations in K⁺-dependent Na⁺-Ca²⁺ exchangers associated with amelogenesis imperfecta and non-syndromic oculocutaneous albinism, *J. Biol. Chem.* 291 (2016) 13113–13123, <https://doi.org/10.1074/jbc.M116.728824>.
- [103] A.H. Jalloul, R.T. Szerencsei, T.P. Rogasevskaia, P.P.M. Schnetkamp, Structure-function relationships of K⁺-dependent Na⁺/Ca²⁺ exchangers (NCKX), *Cell Calcium* 86 (2020) 102153, <https://doi.org/10.1016/j.ceca.2019.102153>.
- [104] J. Liao, H. Li, W. Zeng, D.B. Sauer, R. Belmares, Y. Jiang, Structural insight into the ion-exchange mechanism of the sodium/calcium exchanger, *Science* 335 (2012) 686–690, <https://doi.org/10.1126/science.1215759>.
- [105] J. She, W. Zeng, J. Guo, Q. Chen, X. Bai, Y. Jiang, Structural mechanisms of phospholipid activation of the human TPC2 channel, *eLife* 8 (2019) e45222, <https://doi.org/10.7554/eLife.45222>.
- [106] C. Cang, B. Bekele, D. Ren, The voltage-gated sodium channel TPC1 confers endolysosomal excitability, *Nat. Chem. Biol.* 10 (2014) 463–469, <https://doi.org/10.1038/nchembio.1522>.
- [107] T. Shimomura, Y. Kubo, Phosphoinositides modulate the voltage dependence of two-pore channel 3, *J. Gen. Physiol.* 151 (2019) 986–1006, <https://doi.org/10.1085/jgp.201812285>.
- [108] A.J. Morgan, A. Galione, Two-pore channels (TPCs): current controversies: prospects & overviews, *BioEssays* 36 (2013) 173–183, <https://doi.org/10.1002/bies.201300118>.
- [109] C. Grimm, L.M. Holdt, C.-C. Chen, S. Hassan, C. Müller, S. Jörs, et al., High susceptibility to fatty liver disease in two-pore channel 2-deficient mice, *Nat. Commun.* 5 (2014) 4699, <https://doi.org/10.1038/ncomms5699>.
- [110] M. Ruas, K. Rietdorf, A. Arredouani, L.C. Davis, E. Lloyd-Evans, H. Koegel, et al., Purified TPC isoforms form NAADP receptors with distinct roles for Ca²⁺ signaling and endolysosomal trafficking, *Curr. Biol.* 20 (2010) 703–709, <https://doi.org/10.1016/j.cub.2010.02.049>.
- [111] S.J. Pitt, T.M. Funnell, M. Sitsapesan, E. Venturi, K. Rietdorf, M. Ruas, et al., TPC2 is a novel NAADP-sensitive Ca²⁺ release channel, operating as a dual sensor of luminal pH and Ca²⁺, *J. Biol. Chem.* 285 (2010) 35039–35046, <https://doi.org/10.1074/jbc.M110.156927>.
- [112] N. Tugba Durlu-Kandilci, M. Ruas, K.-T. Chuang, A. Brading, J. Parrington, A. Galione, TPC2 proteins mediate nicotinic acid adenine dinucleotide phosphate (NAADP)- and agonist-evoked contractions of smooth muscle, *J. Biol. Chem.* 285 (2010) 24925–24932, <https://doi.org/10.1074/jbc.M110.129833>.
- [113] A. Jha, M. Ahuja, S. Patel, E. Brailoiu, S. Muallem, Convergent regulation of the lysosomal two-pore channel-2 by Mg²⁺, NAADP, PI(3,5)P₂ and multiple protein kinases, *EMBO J.* 33 (2014) 501–511, <https://doi.org/10.1002/emboj.201387035>.
- [114] O.A. Ogunbayo, J. Duan, J. Xiong, Q. Wang, X. Feng, J. Ma, et al., mTORC1 controls lysosomal Ca²⁺ release through the two-pore channel TPC2, *Sci. Signal.* 11 (2018) eaao5775, <https://doi.org/10.1126/scisignal.aao5775>.
- [115] X. Wang, X. Zhang, X. Dong, M. Samie, X. Li, X. Cheng, et al., TPC proteins are phosphoinositide-activated sodium-selective ion channels in endosomes and lysosomes, *Cell* 151 (2012) 372–383, <https://doi.org/10.1016/j.cell.2012.08.036>.
- [116] T. Notomi, M. Kuno, A. Hiyama, T. Nozaki, K. Ohura, Y. Ezura, et al., Role of lysosomal channel protein TPC2 in osteoclast differentiation and bone remodeling under normal and low-magnesium conditions, *J. Biol. Chem.* 292 (2017) 20998–21010, <https://doi.org/10.1074/jbc.M117.780072>.
- [117] J. Guo, W. Zeng, Y. Jiang, Tuning the ion selectivity of two-pore channels, *Proc. Natl. Acad. Sci. U. S. A.* 114 (2017) 1009–1014, <https://doi.org/10.1073/pnas.1616191114>.
- [118] O.N.P. Nguyen, C. Grimm, L.S. Schneider, Y.-K. Chao, C. Atzberger, K. Bartel, et al., Two-pore channel function is crucial for the migration of invasive cancer cells, *Cancer Res.* 77 (2017) 1427–1438, <https://doi.org/10.1158/0008-5472.CAN-16-0852>.
- [119] A. Favia, M. Desideri, G. Gambarà, A. D'Alessio, M. Ruas, B. Esposito, et al., VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca²⁺ signaling, *Proc. Natl. Acad. Sci. USA* 111 (2014) E4706–E4715, <https://doi.org/10.1073/pnas.1406029111>.
- [120] C. Cang, Y. Zhou, B. Navarro, Y. Seo, K. Aranda, L. Shi, et al., mTOR regulates lysosomal ATP-sensitive two-pore Na⁺ channels to adapt to metabolic state, *Cell* 152 (2013) 778–790, <https://doi.org/10.1016/j.cell.2013.01.023>.
- [121] V. García-Rúa, S. Feijóo-Bandín, D. Rodríguez-Penas, A. Mosquera-Leal, E. Abu-Asi, A. Beiras, et al., Endolysosomal two-pore channels regulate autophagy in cardiomyocytes: TPCs regulate autophagy in cardiomyocytes, *J. Physiol.* 594 (2016) 3061–3077, <https://doi.org/10.1113/JP271332>.
- [122] Y. Sakurai, A.A. Kolokoltsov, C.-C. Chen, M.W. Tidwell, W.E. Bauta, N. Klugbauer, et al., Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment, *Science* 347 (2015) 995–998, <https://doi.org/10.1126/science.1258758>.
- [123] G.S. Gunaratne, Y. Yang, F. Li, T.F. Walseth, J.S. Marchant, NAADP-dependent Ca²⁺ signaling regulates Middle East respiratory syndrome-coronavirus pseudovirus translocation through the endolysosomal system, *Cell Calcium* 75 (2018) 30–41, <https://doi.org/10.1016/j.ceca.2018.08.003>.
- [124] C.J. Penny, K. Vassileva, A. Jha, Y. Yuan, X. Chee, E. Yates, et al., Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers, *Biochim. Biophys. Acta. Mol. Cell. Res.* 1866 (2019) 1151–1161, <https://doi.org/10.1016/j.bbmc.2018.10.022>.
- [125] P. Sulem, D.F. Gudbjartsson, S.N. Stacey, A. Helgason, T. Rafnar, M. Jakobsdottir, et al., Two newly identified genetic determinants of pigmentation in Europeans, *Nat. Genet.* 40 (2008) 835–837, <https://doi.org/10.1038/ng.160>.
- [126] N.W. Bellono, I.E. Escobar, E. Oancea, A melanosomal two-pore sodium channel regulates pigmentation, *Sci. Rep.* 6 (2016) 26570, <https://doi.org/10.1038/srep26570>.
- [127] D.W. Cox, Disorders of copper transport, *Br. Med. Bull.* 55 (1999) 544–555, <https://doi.org/10.1258/0007142991902619>.
- [128] C. Hartwig, S.A. Zlatić, M. Wallin, A. Vrailes-Mortimer, C.J. Fahrni, V. Faundez, Trafficking mechanisms of P-type ATPase copper transporters, *Curr. Opin. Cell Biol.* 59 (2019) 24–33, <https://doi.org/10.1016/j.cob.2019.02.009>.

- [129] S.G. Kaler, ATP7A-related copper transport diseases—emerging concepts and future trends, *Nat. Rev. Neurol.* 7 (2011) 15–29, <https://doi.org/10.1038/nrneurol.2010.180>.
- [130] M.J. Francis, E.E. Jones, E.R. Levy, S. Ponnambalam, J. Chelly, A.P. Monaco, A Golgi localization signal identified in the Menkes recombinant protein, *Hum. Mol. Genet.* 7 (1998) 1245–1252, <https://doi.org/10.1093/hmg/7.8.1245>.
- [131] M.J. Petris, J. Camakaris, M. Greenough, S. LaFontaine, J.F. Mercer, A C-terminal di-leucine is required for localization of the Menkes protein in the *trans*-Golgi network, *Hum. Mol. Genet.* 7 (1998) 2063–2071, <https://doi.org/10.1093/hmg/7.13.2063>.
- [132] M.J. Petris, J.F. Mercer, J.G. Culvenor, P. Lockhart, P.A. Gleeson, J. Camakaris, Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking, *EMBO J.* 15 (1996) 6084–6095, <https://doi.org/10.1002/j.1460-2075.1996.tb00997.x>.
- [133] C. Cobbold, S. Ponnambalam, M.J. Francis, A.P. Monaco, Novel membrane traffic steps regulate the exocytosis of the Menkes disease ATPase, *Hum. Mol. Genet.* 11 (2002) 2855–2866, <https://doi.org/10.1093/hmg/11.23.2855>.
- [134] C. Cobbold, J. Coventry, S. Ponnambalam, A.P. Monaco, The Menkes disease ATPase (ATP7A) is internalized via a Rac1-regulated, clathrin- and caveolae-independent pathway, *Hum. Mol. Genet.* 12 (2003) 1523–1533, <https://doi.org/10.1093/hmg/ddg166>.
- [135] P. Gourdon, O. Sitsel, J.L. Karlsen, L.B. Møller, P. Nissen, Structural models of the human copper P-type ATPase ATP7A and ATP7B, *Biol. Chem.* 393 (2012) 205–216, <https://doi.org/10.1515/hsz-2011-0249>.
- [136] C.D. Kline, B.F. Gambill, M. Mayfield, S. Lutsenko, N.J. Blackburn, pH-regulated metal–ligand switching in the HM loop of ATP7A: a new paradigm for metal transfer chemistry, *Metallomics* 8 (2016) 729–733, <https://doi.org/10.1039/C6MT00062B>.
- [137] A.B. Novikoff, A. Albala, L. Biempica, Ultrastructural and cytochemical observations on B-16 and Harding-Passey mouse melanomas: the origin of pre-melanosomes and compound melanosomes, *J. Histochem. Cytochem.* 16 (1968) 299–319, <https://doi.org/10.1177/16.5.299>.
- [138] L.B. Møller, Z. Tümer, C. Lund, C. Petersen, T. Cole, R. Hanusch, et al., Similar splice-site mutations of the *ATP7A* gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome, *Am. J. Hum. Genet.* 66 (2000) 1211–1220, <https://doi.org/10.1086/302857>.
- [139] L.B. Møller, J.T. Bukrinsky, A. Mølgaard, M. Paulsen, C. Lund, Z. Tümer, et al., Identification and analysis of 21 novel disease-causing amino acid substitutions in the conserved part of ATP7A, *Hum. Mutat.* 26 (2005) 84–93, <https://doi.org/10.1002/humu.20190>.
- [140] S.G. Kaler, N.R.M. Buist, C.S. Holmes, D.S. Goldstein, R.C. Miller, W.A. Gahl, Early copper therapy in classic Menkes disease patients with a novel splicing mutation, *Ann. Neurol.* 38 (1995) 921–928, <https://doi.org/10.1002/ana.410380613>.
- [141] N. Juge, Y. Yoshida, S. Yatsushiro, H. Omote, Y. Moriyama, Vesicular glutamate transporter contains two independent transport machineries, *J. Biol. Chem.* 281 (2006) 39499–39506, <https://doi.org/10.1074/jbc.M607670200>.
- [142] S. Nagamori, P. Wiriyasermkul, M.E. Guarch, H. Okuyama, S. Nakagomi, K. Tadagaki, et al., Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1, *Proc. Natl. Acad. Sci. U. S. A.* 113 (2016) 775–780, <https://doi.org/10.1073/pnas.1519959113>.
- [143] N.G. Crawford, D.E. Kelly, M.E.B. Hansen, M.H. Beltrame, S. Fan, S.L. Bowman, et al., Loci associated with skin pigmentation identified in African populations, *Science* 358 (2017) eaan8433, <https://doi.org/10.1126/science.aan8433>.
- [144] K. Adhikari, J. Mendoza-Revilla, A. Sohail, M. Fuentes-Guajardo, J. Lampert, J.C. Chacón-Duque, et al., A GWAS in Latin Americans highlights the convergent evolution of lighter skin pigmentation in Eurasia, *Nat. Commun.* 10 (2019) 358, <https://doi.org/10.1038/s41467-018-08147-0>.